KRAS mutations lead to induced PD-L1 expression and increased CD8+ tumor-infiltrating lymphocytes, reducing tumor-specific T cell functions, which are correlated with an inflammatory TME [99,100]. This evidence concerns the gene KRAS and neoplasm.